ASTRAZEN vs INDSWFTLAB: Stock Comparison
AstraZeneca Pharma India Limited vs Ind-Swift Laboratories Limited
Live data: 22 July 2026, 2:53 PM IST • Source: NSE and company filings
AstraZeneca Pharma India Limited is the larger company by market capitalisation. AstraZeneca Pharma India Limited shows a higher ROE, a higher dividend yield and faster revenue growth, while Ind-Swift Laboratories Limited shows a lower P/E, lower leverage and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Side-by-side comparison of AstraZeneca Pharma India Limited and Ind-Swift Laboratories Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | ASTRAZEN | INDSWFTLAB |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | ASTRAZEN | INDSWFTLAB |
|---|---|---|
| Live Price | ₹8,030 | ₹234.31 |
| Day Change | -0.72% | -1.38% |
| Volume | 2,341 | 3.77 L |
| 52-Week High | ₹9,849.5 | ₹248.45 |
| 52-Week Low | ₹7,551.5 | ₹87.15 |
| Distance from 52W High | -18.47% | -5.69% |
Valuation
| Metric | ASTRAZEN | INDSWFTLAB |
|---|---|---|
| Market Cap | ₹20,000 Cr | ₹2,035 Cr |
| P/E Ratio | 107.88x | 50.25x |
| P/B Ratio | 23.18x | 1.5x |
| EPS | ₹74.91 | ₹4.84 |
| Book Value | ₹349.08 | ₹165.77 |
| Dividend Yield | 0.45% | 0% |
Growth
| Metric | ASTRAZEN | INDSWFTLAB |
|---|---|---|
| Revenue Growth (TTM YoY) | 20.4% | -66.6% |
| EPS Growth (TTM YoY) | -23% | -94.8% |
| Qtr Sales Growth | 20.4% | 22.8% |
| Qtr Profit Growth | -26.6% | 9.35% |
Profitability & Leverage
| Metric | ASTRAZEN | INDSWFTLAB |
|---|---|---|
| ROE | 23.3% | 3.87% |
| ROCE | 29.3% | 4.7% |
| Net Margin | 8.24% | 41.4% |
| Operating Margin | 11.5% | 7.03% |
| Debt to Equity | 0.13x | 0.01x |
Shareholding
As of Mar 2026 • change vs previous quarter| Metric | ASTRAZEN | INDSWFTLAB |
|---|---|---|
| Promoter Holding | 0% | 42.99%▲ 3.49 pp |
| FII Holding | 2.78%▲ 0.07 pp | 13.88%▼ 0.45 pp |
| DII Holding | 5.8%▲ 0.24 pp | 0%▼ 0.68 pp |
| Public Holding | 16.42%▼ 0.31 pp | 43.12%▼ 2.38 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: AstraZeneca Pharma India Limited and Ind-Swift Laboratories Limited.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.